| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Leukemia, Lymphoid | 64 | 1991 | 276 | 2.360 |
Why?
|
| Methotrexate | 56 | 2006 | 999 | 1.670 |
Why?
|
| Mercaptopurine | 24 | 1998 | 130 | 1.390 |
Why?
|
| Meningeal Neoplasms | 23 | 2005 | 441 | 1.030 |
Why?
|
| Macaca mulatta | 64 | 2005 | 717 | 0.990 |
Why?
|
| Antineoplastic Agents | 50 | 2005 | 14289 | 0.670 |
Why?
|
| Injections, Spinal | 36 | 2005 | 257 | 0.630 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 27 | 2011 | 2796 | 0.600 |
Why?
|
| Neoplasms | 30 | 2023 | 15193 | 0.570 |
Why?
|
| Central Nervous System Diseases | 10 | 1996 | 129 | 0.520 |
Why?
|
| Internet | 2 | 2022 | 706 | 0.490 |
Why?
|
| Child | 113 | 2023 | 29154 | 0.460 |
Why?
|
| Cyclophosphamide | 13 | 2005 | 3001 | 0.440 |
Why?
|
| Leukemia | 16 | 1996 | 1635 | 0.420 |
Why?
|
| Cancer Survivors | 1 | 2018 | 650 | 0.380 |
Why?
|
| Survivors | 2 | 2022 | 1031 | 0.370 |
Why?
|
| Child, Preschool | 80 | 2018 | 16273 | 0.370 |
Why?
|
| Injections, Intravenous | 26 | 1996 | 573 | 0.330 |
Why?
|
| Ribonucleosides | 6 | 1985 | 40 | 0.330 |
Why?
|
| Cytidine | 3 | 1993 | 24 | 0.320 |
Why?
|
| Zidovudine | 5 | 1993 | 40 | 0.310 |
Why?
|
| Asparaginase | 8 | 1998 | 184 | 0.310 |
Why?
|
| Tretinoin | 4 | 1995 | 623 | 0.300 |
Why?
|
| Half-Life | 21 | 1995 | 259 | 0.300 |
Why?
|
| Injections, Intraventricular | 19 | 2000 | 114 | 0.300 |
Why?
|
| Drug Evaluation | 19 | 1992 | 425 | 0.300 |
Why?
|
| Lymphocytes | 12 | 1993 | 1234 | 0.300 |
Why?
|
| Cytarabine | 15 | 1999 | 1973 | 0.290 |
Why?
|
| Kinetics | 28 | 1992 | 2049 | 0.280 |
Why?
|
| Meningitis | 4 | 2005 | 112 | 0.280 |
Why?
|
| Metabolic Clearance Rate | 16 | 2000 | 231 | 0.280 |
Why?
|
| Humans | 200 | 2023 | 261506 | 0.270 |
Why?
|
| Pediatrics | 3 | 2018 | 1141 | 0.270 |
Why?
|
| gamma-Glutamyl Hydrolase | 3 | 2004 | 12 | 0.270 |
Why?
|
| Antimetabolites, Antineoplastic | 7 | 2004 | 1299 | 0.270 |
Why?
|
| Africa South of the Sahara | 2 | 2023 | 101 | 0.270 |
Why?
|
| Coformycin | 5 | 1982 | 20 | 0.270 |
Why?
|
| Anthraquinones | 3 | 1993 | 27 | 0.270 |
Why?
|
| Infusions, Intravenous | 18 | 2000 | 1382 | 0.260 |
Why?
|
| Adolescent | 82 | 2018 | 31252 | 0.250 |
Why?
|
| Camptothecin | 4 | 1996 | 517 | 0.240 |
Why?
|
| Hematology | 2 | 2018 | 104 | 0.240 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 21 | 2000 | 15862 | 0.240 |
Why?
|
| Acquired Immunodeficiency Syndrome | 7 | 1995 | 362 | 0.230 |
Why?
|
| Nucleotidases | 6 | 1982 | 13 | 0.230 |
Why?
|
| Animals | 82 | 2005 | 59536 | 0.220 |
Why?
|
| Male | 128 | 2018 | 123000 | 0.220 |
Why?
|
| Drug Administration Schedule | 23 | 1999 | 3472 | 0.220 |
Why?
|
| Pyrazoles | 5 | 1998 | 1471 | 0.220 |
Why?
|
| Purine-Nucleoside Phosphorylase | 5 | 1982 | 46 | 0.210 |
Why?
|
| Pentosyltransferases | 4 | 1982 | 25 | 0.200 |
Why?
|
| Subarachnoid Space | 3 | 2000 | 36 | 0.200 |
Why?
|
| Chromatography, High Pressure Liquid | 12 | 1999 | 548 | 0.200 |
Why?
|
| Topotecan | 7 | 2003 | 239 | 0.200 |
Why?
|
| Medical Oncology | 2 | 2011 | 1423 | 0.190 |
Why?
|
| Fluorouracil | 4 | 1992 | 1944 | 0.190 |
Why?
|
| Azacitidine | 4 | 1993 | 1149 | 0.190 |
Why?
|
| Adenosine Deaminase | 6 | 1982 | 94 | 0.190 |
Why?
|
| Biological Availability | 13 | 1998 | 214 | 0.190 |
Why?
|
| Asparagine | 3 | 1993 | 38 | 0.180 |
Why?
|
| Thiotepa | 5 | 1996 | 118 | 0.180 |
Why?
|
| Aziridines | 4 | 1998 | 17 | 0.180 |
Why?
|
| Thioguanine | 6 | 1997 | 68 | 0.180 |
Why?
|
| Decision Support Systems, Clinical | 1 | 2022 | 252 | 0.170 |
Why?
|
| Infant | 41 | 2018 | 13310 | 0.170 |
Why?
|
| Nucleoside Deaminases | 4 | 1982 | 33 | 0.170 |
Why?
|
| Benzoquinones | 4 | 1998 | 108 | 0.170 |
Why?
|
| B-Lymphocytes | 11 | 1995 | 1294 | 0.170 |
Why?
|
| Nutrition Disorders | 1 | 1998 | 57 | 0.160 |
Why?
|
| Hematologic Diseases | 1 | 2018 | 242 | 0.150 |
Why?
|
| Dose-Response Relationship, Drug | 18 | 2000 | 4938 | 0.150 |
Why?
|
| Acridines | 2 | 1998 | 12 | 0.140 |
Why?
|
| Adult | 72 | 2006 | 77950 | 0.140 |
Why?
|
| Administration, Oral | 13 | 1998 | 1544 | 0.140 |
Why?
|
| Infusions, Parenteral | 9 | 2000 | 191 | 0.140 |
Why?
|
| T-Lymphocytes | 16 | 1987 | 3869 | 0.140 |
Why?
|
| Polyglutamic Acid | 2 | 1987 | 47 | 0.140 |
Why?
|
| Patient Care Planning | 1 | 2018 | 297 | 0.130 |
Why?
|
| Melphalan | 2 | 1995 | 834 | 0.130 |
Why?
|
| Nutritional Status | 1 | 1998 | 337 | 0.130 |
Why?
|
| Amifostine | 1 | 1995 | 97 | 0.130 |
Why?
|
| Central Nervous System | 3 | 1995 | 436 | 0.130 |
Why?
|
| Leukemia, Experimental | 3 | 1988 | 78 | 0.130 |
Why?
|
| Brain Neoplasms | 7 | 1998 | 4849 | 0.120 |
Why?
|
| Triazoles | 2 | 1990 | 617 | 0.120 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 3 | 1996 | 749 | 0.120 |
Why?
|
| Lymphoma | 6 | 1989 | 1467 | 0.120 |
Why?
|
| Hypoxanthines | 3 | 1993 | 4 | 0.120 |
Why?
|
| Gene Rearrangement, T-Lymphocyte | 3 | 1995 | 67 | 0.120 |
Why?
|
| Burkitt Lymphoma | 9 | 1999 | 335 | 0.120 |
Why?
|
| Time Factors | 24 | 1995 | 12926 | 0.120 |
Why?
|
| Guideline Adherence | 1 | 2018 | 636 | 0.110 |
Why?
|
| Azirines | 2 | 1984 | 5 | 0.110 |
Why?
|
| Genes, Immunoglobulin | 2 | 1995 | 87 | 0.110 |
Why?
|
| Myelin Basic Protein | 2 | 1985 | 85 | 0.110 |
Why?
|
| Rhabdomyosarcoma | 6 | 1998 | 341 | 0.110 |
Why?
|
| Genes, p53 | 2 | 1994 | 1090 | 0.110 |
Why?
|
| Prednisone | 8 | 1998 | 984 | 0.110 |
Why?
|
| Meningioma | 1 | 1995 | 289 | 0.110 |
Why?
|
| Female | 73 | 2018 | 141928 | 0.110 |
Why?
|
| Uracil | 1 | 1992 | 64 | 0.110 |
Why?
|
| Cell Survival | 10 | 1994 | 3045 | 0.110 |
Why?
|
| Retroviridae Infections | 1 | 1991 | 17 | 0.100 |
Why?
|
| Nervous System Neoplasms | 3 | 1989 | 36 | 0.100 |
Why?
|
| Gene Rearrangement, B-Lymphocyte | 1 | 1991 | 47 | 0.100 |
Why?
|
| Macaca | 3 | 1983 | 95 | 0.100 |
Why?
|
| Receptors, Antigen, T-Cell, alpha-beta | 2 | 1991 | 173 | 0.100 |
Why?
|
| Circadian Rhythm | 4 | 1991 | 330 | 0.100 |
Why?
|
| Receptors, Antigen, T-Cell, gamma-delta | 2 | 1991 | 166 | 0.100 |
Why?
|
| Cerebral Ventricles | 6 | 2000 | 98 | 0.100 |
Why?
|
| Hypoxanthine Phosphoribosyltransferase | 2 | 1993 | 30 | 0.100 |
Why?
|
| Clinical Trials as Topic | 8 | 2011 | 3719 | 0.100 |
Why?
|
| Radiotherapy, High-Energy | 2 | 1990 | 295 | 0.100 |
Why?
|
| Sarcoma, Ewing | 5 | 1998 | 406 | 0.100 |
Why?
|
| Brain Diseases | 5 | 1990 | 403 | 0.100 |
Why?
|
| Delivery of Health Care | 1 | 2018 | 860 | 0.100 |
Why?
|
| Infusion Pumps | 1 | 1990 | 61 | 0.090 |
Why?
|
| Brain | 10 | 2000 | 4113 | 0.090 |
Why?
|
| Attention | 2 | 1990 | 281 | 0.090 |
Why?
|
| Rosette Formation | 4 | 1982 | 38 | 0.090 |
Why?
|
| Vincristine | 11 | 1998 | 1511 | 0.090 |
Why?
|
| Tumor Cells, Cultured | 7 | 1994 | 5395 | 0.090 |
Why?
|
| Liver | 6 | 1998 | 2961 | 0.090 |
Why?
|
| Peptides | 2 | 1987 | 1479 | 0.090 |
Why?
|
| Phosphoribosyl Pyrophosphate | 2 | 1986 | 6 | 0.090 |
Why?
|
| Folic Acid Antagonists | 2 | 1988 | 45 | 0.090 |
Why?
|
| Drug Interactions | 6 | 1992 | 553 | 0.090 |
Why?
|
| Antigens, Surface | 4 | 1988 | 295 | 0.090 |
Why?
|
| Education, Medical, Graduate | 2 | 2018 | 671 | 0.090 |
Why?
|
| Physicians, Women | 1 | 2011 | 105 | 0.090 |
Why?
|
| Testicular Neoplasms | 4 | 1985 | 529 | 0.090 |
Why?
|
| Schools, Medical | 1 | 2010 | 132 | 0.090 |
Why?
|
| Polyethylene Glycols | 1 | 1993 | 615 | 0.080 |
Why?
|
| Injections, Intramuscular | 5 | 1993 | 255 | 0.080 |
Why?
|
| Deoxyribonucleosides | 1 | 1988 | 3 | 0.080 |
Why?
|
| Growth Hormone | 4 | 1984 | 226 | 0.080 |
Why?
|
| Drug Resistance | 7 | 1993 | 587 | 0.080 |
Why?
|
| Pyrimidine Nucleosides | 1 | 1988 | 7 | 0.080 |
Why?
|
| Hydantoins | 1 | 1988 | 6 | 0.080 |
Why?
|
| Combined Modality Therapy | 10 | 1998 | 8865 | 0.080 |
Why?
|
| Razoxane | 2 | 1996 | 22 | 0.080 |
Why?
|
| Pyrimidines | 2 | 1992 | 3518 | 0.080 |
Why?
|
| Minority Groups | 1 | 2011 | 322 | 0.080 |
Why?
|
| Catheterization | 2 | 1990 | 410 | 0.080 |
Why?
|
| Protein Binding | 6 | 1998 | 3438 | 0.080 |
Why?
|
| Phenytoin | 1 | 1988 | 71 | 0.080 |
Why?
|
| BCG Vaccine | 4 | 1979 | 399 | 0.080 |
Why?
|
| Nitrogen Mustard Compounds | 1 | 1988 | 73 | 0.080 |
Why?
|
| Leucovorin | 4 | 1995 | 332 | 0.080 |
Why?
|
| Recombinant Proteins | 5 | 2004 | 2927 | 0.080 |
Why?
|
| Prostate-Specific Antigen | 1 | 2011 | 993 | 0.080 |
Why?
|
| Antiviral Agents | 3 | 1995 | 1230 | 0.080 |
Why?
|
| Up-Regulation | 2 | 1995 | 2450 | 0.080 |
Why?
|
| Cryptococcosis | 1 | 1988 | 63 | 0.080 |
Why?
|
| Ifosfamide | 1 | 1988 | 344 | 0.080 |
Why?
|
| Allopurinol | 2 | 1986 | 54 | 0.080 |
Why?
|
| Practice Guidelines as Topic | 1 | 2018 | 2403 | 0.080 |
Why?
|
| Leadership | 1 | 2010 | 254 | 0.080 |
Why?
|
| Prednisolone | 2 | 1987 | 123 | 0.070 |
Why?
|
| Genes | 6 | 1989 | 491 | 0.070 |
Why?
|
| Hematologic Neoplasms | 1 | 2018 | 1870 | 0.070 |
Why?
|
| Memory Disorders | 1 | 1990 | 295 | 0.070 |
Why?
|
| Receptors, Antigen, T-Cell | 6 | 1995 | 1146 | 0.070 |
Why?
|
| Genetic Therapy | 3 | 2000 | 1616 | 0.070 |
Why?
|
| Pentosephosphates | 1 | 1986 | 11 | 0.070 |
Why?
|
| Alkaline Phosphatase | 2 | 1987 | 207 | 0.070 |
Why?
|
| Acute Disease | 10 | 1986 | 2422 | 0.070 |
Why?
|
| Antibiotics, Antineoplastic | 3 | 1999 | 726 | 0.070 |
Why?
|
| Amitriptyline | 1 | 1986 | 38 | 0.070 |
Why?
|
| Otitis | 1 | 1985 | 8 | 0.070 |
Why?
|
| DNA | 2 | 1993 | 2693 | 0.070 |
Why?
|
| Leydig Cells | 1 | 1985 | 39 | 0.070 |
Why?
|
| Medication Errors | 2 | 2004 | 174 | 0.070 |
Why?
|
| Morphine | 1 | 1987 | 308 | 0.070 |
Why?
|
| Communication Disorders | 1 | 1985 | 8 | 0.070 |
Why?
|
| Purines | 3 | 1981 | 273 | 0.070 |
Why?
|
| Mastoiditis | 1 | 1985 | 26 | 0.070 |
Why?
|
| Hepatitis B | 2 | 1986 | 258 | 0.070 |
Why?
|
| Leukemia L5178 | 1 | 1985 | 3 | 0.070 |
Why?
|
| Recurrence | 11 | 1999 | 4758 | 0.070 |
Why?
|
| Thioinosine | 1 | 1984 | 2 | 0.070 |
Why?
|
| Quinazolines | 3 | 1988 | 923 | 0.070 |
Why?
|
| Leukocyte Count | 9 | 1992 | 684 | 0.070 |
Why?
|
| Probenecid | 3 | 2000 | 5 | 0.060 |
Why?
|
| Hypothalamo-Hypophyseal System | 3 | 1982 | 127 | 0.060 |
Why?
|
| Pentostatin | 5 | 1982 | 119 | 0.060 |
Why?
|
| Brain Abscess | 1 | 1985 | 60 | 0.060 |
Why?
|
| Inosine | 1 | 1984 | 39 | 0.060 |
Why?
|
| Complement System Proteins | 3 | 1982 | 139 | 0.060 |
Why?
|
| Isoenzymes | 4 | 1993 | 614 | 0.060 |
Why?
|
| Testis | 3 | 1987 | 717 | 0.060 |
Why?
|
| Prognosis | 8 | 2011 | 21713 | 0.060 |
Why?
|
| Feasibility Studies | 2 | 2005 | 2292 | 0.060 |
Why?
|
| Societies, Medical | 1 | 2011 | 1335 | 0.060 |
Why?
|
| Carrier Proteins | 1 | 1993 | 2022 | 0.060 |
Why?
|
| Absorption | 2 | 1998 | 81 | 0.060 |
Why?
|
| Neutropenia | 6 | 1998 | 968 | 0.060 |
Why?
|
| Aminoacridines | 1 | 1984 | 23 | 0.060 |
Why?
|
| Folic Acid | 1 | 1987 | 349 | 0.060 |
Why?
|
| Daunorubicin | 3 | 1999 | 301 | 0.060 |
Why?
|
| Ribavirin | 1 | 1985 | 178 | 0.060 |
Why?
|
| Antifungal Agents | 1 | 1990 | 834 | 0.060 |
Why?
|
| L-Lactate Dehydrogenase | 2 | 1982 | 299 | 0.060 |
Why?
|
| Catheters, Indwelling | 3 | 1990 | 374 | 0.060 |
Why?
|
| Tomography, X-Ray Computed | 10 | 1990 | 7551 | 0.060 |
Why?
|
| Models, Biological | 6 | 1997 | 3254 | 0.060 |
Why?
|
| Leukemia L1210 | 2 | 1984 | 54 | 0.060 |
Why?
|
| Spinal Cord Neoplasms | 1 | 1985 | 142 | 0.060 |
Why?
|
| Receptors, Fc | 2 | 1980 | 69 | 0.060 |
Why?
|
| Leukopenia | 3 | 1991 | 151 | 0.060 |
Why?
|
| Interferon Type I | 1 | 1985 | 250 | 0.060 |
Why?
|
| Injections, Subcutaneous | 3 | 1989 | 334 | 0.060 |
Why?
|
| Cerebrospinal Fluid | 3 | 2000 | 120 | 0.060 |
Why?
|
| Receptors, Interleukin-2 | 4 | 1992 | 186 | 0.060 |
Why?
|
| Leukemia-Lymphoma, Adult T-Cell | 3 | 1994 | 65 | 0.060 |
Why?
|
| Leukemia, Myeloid, Acute | 4 | 1992 | 6915 | 0.060 |
Why?
|
| Doxorubicin | 4 | 1996 | 3005 | 0.060 |
Why?
|
| Receptors, Immunologic | 3 | 1990 | 309 | 0.060 |
Why?
|
| Antibodies | 3 | 1991 | 838 | 0.060 |
Why?
|
| Thrombocythemia, Essential | 1 | 1984 | 162 | 0.050 |
Why?
|
| Tetrahydrouridine | 1 | 1982 | 6 | 0.050 |
Why?
|
| Dideoxyadenosine | 2 | 1999 | 4 | 0.050 |
Why?
|
| Stomatitis | 2 | 1985 | 183 | 0.050 |
Why?
|
| Agranulocytosis | 4 | 1990 | 79 | 0.050 |
Why?
|
| Drug Screening Assays, Antitumor | 4 | 1994 | 566 | 0.050 |
Why?
|
| Intelligence | 2 | 1990 | 126 | 0.050 |
Why?
|
| Seminiferous Tubules | 1 | 1982 | 52 | 0.050 |
Why?
|
| Survivorship | 1 | 2022 | 109 | 0.050 |
Why?
|
| Uridine | 1 | 1982 | 59 | 0.050 |
Why?
|
| Blood-Brain Barrier | 4 | 1991 | 238 | 0.050 |
Why?
|
| Extracellular Space | 1 | 1982 | 132 | 0.050 |
Why?
|
| Central Nervous System Neoplasms | 1 | 2006 | 502 | 0.050 |
Why?
|
| Intestinal Absorption | 3 | 1993 | 211 | 0.050 |
Why?
|
| Species Specificity | 3 | 1990 | 777 | 0.050 |
Why?
|
| Dexamethasone | 1 | 1987 | 1450 | 0.050 |
Why?
|
| Deoxyadenosines | 1 | 1981 | 42 | 0.050 |
Why?
|
| Cytotoxicity, Immunologic | 5 | 1988 | 675 | 0.050 |
Why?
|
| Cell Line | 10 | 1995 | 5114 | 0.050 |
Why?
|
| Neuroblastoma | 2 | 1998 | 686 | 0.050 |
Why?
|
| Radiation Injuries | 4 | 1985 | 1411 | 0.050 |
Why?
|
| Testosterone | 2 | 1985 | 619 | 0.050 |
Why?
|
| Bacterial Infections | 3 | 1991 | 479 | 0.050 |
Why?
|
| Drug Stability | 2 | 1993 | 105 | 0.050 |
Why?
|
| Hypoxanthine | 2 | 1993 | 8 | 0.050 |
Why?
|
| Binding Sites, Antibody | 2 | 1989 | 135 | 0.050 |
Why?
|
| Peroxidases | 2 | 1984 | 29 | 0.050 |
Why?
|
| Bone Marrow Transplantation | 2 | 1985 | 1581 | 0.050 |
Why?
|
| Infant, Newborn | 7 | 2018 | 8223 | 0.050 |
Why?
|
| Abnormalities, Drug-Induced | 1 | 1980 | 89 | 0.050 |
Why?
|
| Colony-Forming Units Assay | 2 | 1984 | 249 | 0.050 |
Why?
|
| Uricosuric Agents | 1 | 2000 | 3 | 0.050 |
Why?
|
| Paclitaxel | 3 | 1997 | 1996 | 0.050 |
Why?
|
| Cytidine Deaminase | 3 | 1993 | 83 | 0.050 |
Why?
|
| Hypersensitivity, Delayed | 1 | 1980 | 104 | 0.040 |
Why?
|
| Pinocytosis | 2 | 1977 | 28 | 0.040 |
Why?
|
| Neuropsychological Tests | 3 | 1990 | 1178 | 0.040 |
Why?
|
| Interleukin-2 | 4 | 1992 | 842 | 0.040 |
Why?
|
| Adenosine | 1 | 1981 | 289 | 0.040 |
Why?
|
| Cytotoxins | 2 | 1998 | 66 | 0.040 |
Why?
|
| Drug Therapy, Combination | 10 | 1982 | 2315 | 0.040 |
Why?
|
| Granulocytes | 3 | 1979 | 224 | 0.040 |
Why?
|
| Chemotaxis | 2 | 1977 | 138 | 0.040 |
Why?
|
| Sezary Syndrome | 1 | 1980 | 159 | 0.040 |
Why?
|
| Cognition Disorders | 1 | 1985 | 786 | 0.040 |
Why?
|
| Capacity Building | 1 | 2018 | 30 | 0.040 |
Why?
|
| Bone Marrow Diseases | 2 | 1993 | 177 | 0.040 |
Why?
|
| Risk Factors | 2 | 2018 | 17523 | 0.040 |
Why?
|
| Antibodies, Monoclonal | 4 | 1996 | 4367 | 0.040 |
Why?
|
| Adrenal Glands | 1 | 1979 | 122 | 0.040 |
Why?
|
| Adrenal Insufficiency | 1 | 1979 | 49 | 0.040 |
Why?
|
| Drug Hypersensitivity | 1 | 1980 | 128 | 0.040 |
Why?
|
| Drug Evaluation, Preclinical | 2 | 1991 | 503 | 0.040 |
Why?
|
| Thionucleotides | 2 | 1998 | 65 | 0.040 |
Why?
|
| Antibody Formation | 3 | 1992 | 383 | 0.040 |
Why?
|
| Immunophenotyping | 2 | 1994 | 1681 | 0.040 |
Why?
|
| Monocytes | 4 | 1981 | 788 | 0.040 |
Why?
|
| Immunoglobulins | 5 | 1987 | 266 | 0.040 |
Why?
|
| Saliva | 1 | 1979 | 231 | 0.040 |
Why?
|
| Osteosarcoma | 4 | 1998 | 929 | 0.040 |
Why?
|
| Drug Overdose | 2 | 2004 | 81 | 0.040 |
Why?
|
| Patient Care | 1 | 2018 | 149 | 0.040 |
Why?
|
| Retinal Neoplasms | 1 | 1999 | 144 | 0.040 |
Why?
|
| Retinoblastoma | 1 | 1999 | 200 | 0.040 |
Why?
|
| Vidarabine | 1 | 1982 | 1341 | 0.040 |
Why?
|
| Leukemia, Myeloid | 2 | 1981 | 941 | 0.040 |
Why?
|
| Carbon Radioisotopes | 2 | 1993 | 116 | 0.040 |
Why?
|
| Fetus | 1 | 1980 | 601 | 0.040 |
Why?
|
| Receptors, Antigen, B-Cell | 4 | 1983 | 171 | 0.040 |
Why?
|
| Gene Amplification | 2 | 1998 | 731 | 0.040 |
Why?
|
| Mathematics | 2 | 1988 | 136 | 0.040 |
Why?
|
| Trimetrexate | 4 | 1995 | 12 | 0.040 |
Why?
|
| Idarubicin | 1 | 1999 | 446 | 0.040 |
Why?
|
| Anti-HIV Agents | 1 | 1999 | 350 | 0.030 |
Why?
|
| Antibody Specificity | 1 | 1976 | 334 | 0.030 |
Why?
|
| Remission, Spontaneous | 8 | 1979 | 119 | 0.030 |
Why?
|
| Congresses as Topic | 1 | 2018 | 298 | 0.030 |
Why?
|
| Receptor-CD3 Complex, Antigen, T-Cell | 1 | 1995 | 6 | 0.030 |
Why?
|
| Thrombocytopenia | 5 | 1998 | 846 | 0.030 |
Why?
|
| Tissue Distribution | 3 | 1987 | 875 | 0.030 |
Why?
|
| Risk | 3 | 2006 | 1972 | 0.030 |
Why?
|
| Mycobacterium bovis | 1 | 1976 | 67 | 0.030 |
Why?
|
| Meninges | 1 | 1995 | 47 | 0.030 |
Why?
|
| Dideoxynucleosides | 1 | 1995 | 19 | 0.030 |
Why?
|
| Immunity, Cellular | 2 | 1978 | 419 | 0.030 |
Why?
|
| Antineoplastic Agents, Phytogenic | 2 | 1997 | 852 | 0.030 |
Why?
|
| Sarcoma | 3 | 1996 | 1725 | 0.030 |
Why?
|
| Rats | 5 | 1990 | 6086 | 0.030 |
Why?
|
| Food | 2 | 1986 | 146 | 0.030 |
Why?
|
| Leukemic Infiltration | 1 | 1995 | 72 | 0.030 |
Why?
|
| Arthritis, Infectious | 1 | 1975 | 68 | 0.030 |
Why?
|
| Soft Tissue Neoplasms | 3 | 1998 | 882 | 0.030 |
Why?
|
| AIDS Dementia Complex | 2 | 1993 | 18 | 0.030 |
Why?
|
| Didanosine | 2 | 1995 | 5 | 0.030 |
Why?
|
| Spinal Puncture | 4 | 1979 | 63 | 0.030 |
Why?
|
| Patient Isolators | 1 | 1974 | 2 | 0.030 |
Why?
|
| Phagocytosis | 2 | 1978 | 260 | 0.030 |
Why?
|
| Fellowships and Scholarships | 1 | 2018 | 390 | 0.030 |
Why?
|
| Protective Clothing | 1 | 1974 | 10 | 0.030 |
Why?
|
| Cardiovascular Agents | 1 | 1996 | 128 | 0.030 |
Why?
|
| Prostatic Neoplasms | 1 | 2011 | 5767 | 0.030 |
Why?
|
| Amphotericin B | 1 | 1975 | 289 | 0.030 |
Why?
|
| Glomerular Filtration Rate | 1 | 1998 | 602 | 0.030 |
Why?
|
| Membrane Glycoproteins | 2 | 1989 | 1073 | 0.030 |
Why?
|
| Lymphoma, Non-Hodgkin | 3 | 2004 | 1039 | 0.030 |
Why?
|
| Blood Proteins | 2 | 1987 | 294 | 0.030 |
Why?
|
| Rats, Inbred Strains | 2 | 1986 | 410 | 0.030 |
Why?
|
| Chemical and Drug Induced Liver Injury | 2 | 1987 | 193 | 0.030 |
Why?
|
| Sulfur Radioisotopes | 1 | 1993 | 26 | 0.030 |
Why?
|
| Glucuronates | 1 | 1993 | 11 | 0.030 |
Why?
|
| Quinolinic Acid | 1 | 1993 | 23 | 0.030 |
Why?
|
| Calcinosis | 2 | 1990 | 423 | 0.030 |
Why?
|
| Macrophages | 3 | 1979 | 1304 | 0.030 |
Why?
|
| Codon | 1 | 1994 | 241 | 0.030 |
Why?
|
| Inactivation, Metabolic | 1 | 1993 | 37 | 0.030 |
Why?
|
| Zalcitabine | 2 | 1990 | 3 | 0.030 |
Why?
|
| Leukocytes | 2 | 1981 | 422 | 0.030 |
Why?
|
| Posture | 1 | 1995 | 215 | 0.030 |
Why?
|
| Mice | 12 | 1995 | 34495 | 0.030 |
Why?
|
| Uridine Kinase | 1 | 1993 | 4 | 0.030 |
Why?
|
| Injections, Intraperitoneal | 2 | 1986 | 197 | 0.030 |
Why?
|
| Cisplatin | 1 | 1981 | 2432 | 0.030 |
Why?
|
| Candidiasis | 1 | 1975 | 262 | 0.030 |
Why?
|
| Bone Marrow | 4 | 1991 | 2358 | 0.030 |
Why?
|
| Taxoids | 1 | 1997 | 967 | 0.030 |
Why?
|
| Lipid Bilayers | 1 | 1993 | 52 | 0.030 |
Why?
|
| Enzymes, Immobilized | 1 | 1993 | 10 | 0.030 |
Why?
|
| Drug Compounding | 1 | 1993 | 70 | 0.030 |
Why?
|
| Aminolevulinic Acid | 1 | 1993 | 19 | 0.030 |
Why?
|
| Ribonucleotides | 1 | 1993 | 52 | 0.030 |
Why?
|
| Hydrolysis | 1 | 1993 | 227 | 0.030 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 1991 | 10035 | 0.030 |
Why?
|
| Clone Cells | 2 | 1991 | 555 | 0.030 |
Why?
|
| Guanosine Triphosphate | 2 | 1998 | 90 | 0.030 |
Why?
|
| Streptococcus pneumoniae | 1 | 1974 | 330 | 0.030 |
Why?
|
| Platelet Count | 2 | 1992 | 490 | 0.030 |
Why?
|
| Neuroectodermal Tumors, Primitive, Peripheral | 3 | 1998 | 36 | 0.030 |
Why?
|
| Middle Aged | 14 | 2004 | 86204 | 0.030 |
Why?
|
| Heart | 2 | 1996 | 1223 | 0.030 |
Why?
|
| Antineoplastic Agents, Alkylating | 1 | 1996 | 588 | 0.030 |
Why?
|
| Bone Neoplasms | 4 | 1998 | 2576 | 0.030 |
Why?
|
| Hydrocortisone | 3 | 1985 | 388 | 0.030 |
Why?
|
| Cell Cycle | 2 | 1993 | 2084 | 0.030 |
Why?
|
| Skin Neoplasms | 2 | 1993 | 4654 | 0.030 |
Why?
|
| Paralysis | 1 | 1992 | 51 | 0.030 |
Why?
|
| Treatment Outcome | 5 | 2006 | 32848 | 0.030 |
Why?
|
| Follow-Up Studies | 7 | 1990 | 14889 | 0.030 |
Why?
|
| 5'-Nucleotidase | 2 | 1982 | 61 | 0.030 |
Why?
|
| Leukemia, Promyelocytic, Acute | 1 | 1995 | 430 | 0.030 |
Why?
|
| Drug Carriers | 1 | 1993 | 327 | 0.030 |
Why?
|
| Receptors, Retinoic Acid | 1 | 1993 | 365 | 0.030 |
Why?
|
| Haplorhini | 4 | 1979 | 130 | 0.020 |
Why?
|
| Drug Industry | 1 | 1991 | 88 | 0.020 |
Why?
|
| Vidarabine Phosphate | 1 | 1990 | 50 | 0.020 |
Why?
|
| Piperazines | 1 | 1980 | 2101 | 0.020 |
Why?
|
| Chromosome Aberrations | 1 | 1998 | 1960 | 0.020 |
Why?
|
| Perfusion | 2 | 1984 | 293 | 0.020 |
Why?
|
| Lymphocyte Cooperation | 2 | 1981 | 11 | 0.020 |
Why?
|
| Necrosis | 1 | 1992 | 580 | 0.020 |
Why?
|
| Immunoglobulin M | 3 | 1980 | 347 | 0.020 |
Why?
|
| Luteinizing Hormone | 3 | 1985 | 165 | 0.020 |
Why?
|
| Biological Transport, Active | 2 | 1987 | 131 | 0.020 |
Why?
|
| Aspartate Aminotransferases | 2 | 1987 | 153 | 0.020 |
Why?
|
| Verbal Learning | 1 | 1990 | 84 | 0.020 |
Why?
|
| Cross Infection | 1 | 1974 | 544 | 0.020 |
Why?
|
| Molecular Structure | 1 | 1990 | 515 | 0.020 |
Why?
|
| Follicle Stimulating Hormone | 3 | 1985 | 241 | 0.020 |
Why?
|
| Hypothyroidism | 1 | 1991 | 204 | 0.020 |
Why?
|
| Cell Membrane | 3 | 1983 | 850 | 0.020 |
Why?
|
| Immunotherapy | 2 | 2000 | 3341 | 0.020 |
Why?
|
| Erythrocytes | 3 | 1998 | 339 | 0.020 |
Why?
|
| Nervous System | 2 | 1988 | 165 | 0.020 |
Why?
|
| Alanine Transaminase | 2 | 1987 | 227 | 0.020 |
Why?
|
| Meningitis, Bacterial | 1 | 1990 | 89 | 0.020 |
Why?
|
| Leukemia P388 | 1 | 1988 | 25 | 0.020 |
Why?
|
| Dogs | 1 | 1990 | 1155 | 0.020 |
Why?
|
| Professional Competence | 1 | 2010 | 136 | 0.020 |
Why?
|
| Career Choice | 1 | 2011 | 232 | 0.020 |
Why?
|
| HIV-1 | 1 | 1993 | 653 | 0.020 |
Why?
|
| Physostigmine | 1 | 1988 | 8 | 0.020 |
Why?
|
| Major Histocompatibility Complex | 1 | 1988 | 91 | 0.020 |
Why?
|
| Immunotoxins | 1 | 1989 | 117 | 0.020 |
Why?
|
| Karyotyping | 3 | 1998 | 1022 | 0.020 |
Why?
|
| Genotype | 2 | 1994 | 4109 | 0.020 |
Why?
|
| Mice, Inbred BALB C | 1 | 1993 | 2314 | 0.020 |
Why?
|
| Fever | 1 | 1991 | 497 | 0.020 |
Why?
|
| Sexual Maturation | 2 | 1985 | 65 | 0.020 |
Why?
|
| Spinal Cord | 1 | 1992 | 690 | 0.020 |
Why?
|
| Chromosome Deletion | 2 | 1992 | 1005 | 0.020 |
Why?
|
| Intracranial Pressure | 3 | 1978 | 180 | 0.020 |
Why?
|
| Permeability | 1 | 1988 | 167 | 0.020 |
Why?
|
| Biopsy | 2 | 1993 | 3443 | 0.020 |
Why?
|
| Glutathione Transferase | 1 | 1989 | 359 | 0.020 |
Why?
|
| Fluconazole | 1 | 1988 | 103 | 0.020 |
Why?
|
| Antibody-Dependent Cell Cytotoxicity | 4 | 1981 | 84 | 0.020 |
Why?
|
| Specimen Handling | 2 | 1987 | 299 | 0.020 |
Why?
|
| Immunoglobulin G | 3 | 1980 | 1021 | 0.020 |
Why?
|
| Skin | 1 | 1993 | 1259 | 0.020 |
Why?
|
| Thymus Gland | 1 | 1988 | 294 | 0.020 |
Why?
|
| Texas | 1 | 2018 | 6311 | 0.020 |
Why?
|
| Drug Synergism | 1 | 1990 | 1313 | 0.020 |
Why?
|
| Wiskott-Aldrich Syndrome | 2 | 1976 | 24 | 0.020 |
Why?
|
| RNA | 2 | 1989 | 1013 | 0.020 |
Why?
|
| Brain Chemistry | 1 | 1987 | 145 | 0.020 |
Why?
|
| Hepatitis B Surface Antigens | 1 | 1986 | 84 | 0.020 |
Why?
|
| Killer Cells, Natural | 3 | 1981 | 904 | 0.020 |
Why?
|
| DNA, Neoplasm | 3 | 1990 | 1910 | 0.020 |
Why?
|
| Logistic Models | 1 | 1993 | 3441 | 0.020 |
Why?
|
| HIV | 1 | 1987 | 229 | 0.020 |
Why?
|
| Structure-Activity Relationship | 1 | 1988 | 931 | 0.020 |
Why?
|
| Radiotherapy Dosage | 3 | 1985 | 3842 | 0.020 |
Why?
|
| Pentetic Acid | 2 | 1985 | 48 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 1993 | 4298 | 0.020 |
Why?
|
| Blood Cells | 1 | 1986 | 127 | 0.020 |
Why?
|
| Cell Count | 1 | 1986 | 508 | 0.020 |
Why?
|
| Reference Standards | 1 | 1986 | 339 | 0.020 |
Why?
|
| Cranial Fossa, Posterior | 1 | 1985 | 49 | 0.020 |
Why?
|
| Orbital Neoplasms | 2 | 1978 | 224 | 0.020 |
Why?
|
| Blood Platelets | 2 | 1984 | 731 | 0.020 |
Why?
|
| Cognition | 2 | 2006 | 968 | 0.020 |
Why?
|
| Cell Differentiation | 2 | 1994 | 4078 | 0.020 |
Why?
|
| Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 1990 | 482 | 0.020 |
Why?
|
| Nucleotides | 1 | 1985 | 164 | 0.020 |
Why?
|
| Chromosome Mapping | 1 | 1988 | 1471 | 0.020 |
Why?
|
| Mutation | 3 | 1994 | 15179 | 0.020 |
Why?
|
| Base Sequence | 4 | 1995 | 4917 | 0.020 |
Why?
|
| Dilatation, Pathologic | 1 | 1985 | 88 | 0.020 |
Why?
|
| Corticotropin-Releasing Hormone | 1 | 1985 | 82 | 0.020 |
Why?
|
| Age Factors | 2 | 1989 | 5377 | 0.020 |
Why?
|
| Glioma | 2 | 1996 | 1963 | 0.020 |
Why?
|
| Glutamates | 1 | 1985 | 130 | 0.020 |
Why?
|
| Cyclohexenes | 1 | 1984 | 11 | 0.020 |
Why?
|
| Arabinofuranosyluracil | 1 | 1984 | 42 | 0.020 |
Why?
|
| United States | 3 | 2011 | 15433 | 0.020 |
Why?
|
| Amsacrine | 1 | 1984 | 61 | 0.020 |
Why?
|
| Molecular Sequence Data | 4 | 1995 | 6089 | 0.020 |
Why?
|
| Body Weight | 1 | 1989 | 1293 | 0.020 |
Why?
|
| Staphylococcal Infections | 1 | 1990 | 672 | 0.010 |
Why?
|
| Neurocognitive Disorders | 1 | 1984 | 69 | 0.010 |
Why?
|
| Lymphocytes, Null | 1 | 1983 | 5 | 0.010 |
Why?
|
| Early Detection of Cancer | 1 | 2011 | 1258 | 0.010 |
Why?
|
| Biological Transport | 1 | 1985 | 597 | 0.010 |
Why?
|
| Cranial Irradiation | 2 | 1998 | 315 | 0.010 |
Why?
|
| Adenosine Triphosphate | 1 | 1985 | 571 | 0.010 |
Why?
|
| Diffusion | 1 | 1983 | 88 | 0.010 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 1988 | 1016 | 0.010 |
Why?
|
| Dacarbazine | 1 | 1985 | 485 | 0.010 |
Why?
|
| Tetrahydrofolate Dehydrogenase | 2 | 1995 | 28 | 0.010 |
Why?
|
| Glutamine | 1 | 1985 | 299 | 0.010 |
Why?
|
| Glutamic Acid | 1 | 1985 | 309 | 0.010 |
Why?
|
| Aged | 4 | 2004 | 70117 | 0.010 |
Why?
|
| Mice, Inbred DBA | 1 | 1982 | 110 | 0.010 |
Why?
|
| Radiotherapy | 3 | 1979 | 1824 | 0.010 |
Why?
|
| Adenosylhomocysteinase | 1 | 1982 | 3 | 0.010 |
Why?
|
| Cerebrovascular Circulation | 1 | 1986 | 471 | 0.010 |
Why?
|
| Immunoglobulin A | 2 | 1980 | 237 | 0.010 |
Why?
|
| In Vitro Techniques | 4 | 1979 | 1618 | 0.010 |
Why?
|
| Oxazoles | 1 | 1982 | 60 | 0.010 |
Why?
|
| Fat Emulsions, Intravenous | 1 | 1982 | 70 | 0.010 |
Why?
|
| Drainage | 1 | 2004 | 416 | 0.010 |
Why?
|
| Adenosine Deaminase Inhibitors | 1 | 1981 | 24 | 0.010 |
Why?
|
| Isoxazoles | 1 | 1982 | 81 | 0.010 |
Why?
|
| Wechsler Scales | 1 | 1981 | 26 | 0.010 |
Why?
|
| Deoxycytidine | 1 | 1987 | 1353 | 0.010 |
Why?
|
| Phenotype | 6 | 1990 | 6295 | 0.010 |
Why?
|
| Translocation, Genetic | 2 | 1995 | 1245 | 0.010 |
Why?
|
| Receptors, Complement | 1 | 1981 | 48 | 0.010 |
Why?
|
| Misonidazole | 1 | 1981 | 11 | 0.010 |
Why?
|
| Hydrolases | 1 | 1982 | 123 | 0.010 |
Why?
|
| Fluorescent Antibody Technique | 2 | 1980 | 1062 | 0.010 |
Why?
|
| Thyrotropin | 3 | 1991 | 119 | 0.010 |
Why?
|
| Cytochalasin B | 1 | 1980 | 10 | 0.010 |
Why?
|
| Kidney | 2 | 1987 | 2146 | 0.010 |
Why?
|
| Colchicine | 1 | 1980 | 52 | 0.010 |
Why?
|
| DNA Nucleotidylexotransferase | 1 | 1980 | 57 | 0.010 |
Why?
|
| Remission Induction | 2 | 1999 | 3569 | 0.010 |
Why?
|
| DNA Replication | 1 | 1985 | 744 | 0.010 |
Why?
|
| Phosphorus Metabolism Disorders | 1 | 1980 | 1 | 0.010 |
Why?
|
| Nitroimidazoles | 1 | 1981 | 100 | 0.010 |
Why?
|
| Demyelinating Diseases | 1 | 1980 | 77 | 0.010 |
Why?
|
| Epilepsy | 1 | 1988 | 883 | 0.010 |
Why?
|
| Uremia | 1 | 1980 | 42 | 0.010 |
Why?
|
| Cytotoxicity Tests, Immunologic | 2 | 1976 | 84 | 0.010 |
Why?
|
| Carbenicillin | 1 | 1979 | 1 | 0.010 |
Why?
|
| Pilot Projects | 1 | 2006 | 2803 | 0.010 |
Why?
|
| Cephalothin | 1 | 1979 | 5 | 0.010 |
Why?
|
| Antigens, Differentiation, T-Lymphocyte | 2 | 1991 | 167 | 0.010 |
Why?
|
| Hypocalcemia | 1 | 1980 | 59 | 0.010 |
Why?
|
| Arabinonucleosides | 1 | 1982 | 437 | 0.010 |
Why?
|
| Algorithms | 1 | 1991 | 3890 | 0.010 |
Why?
|
| Vomiting | 1 | 1981 | 354 | 0.010 |
Why?
|
| Immunocompetence | 1 | 1979 | 75 | 0.010 |
Why?
|
| Lymphocyte Activation | 2 | 1982 | 1688 | 0.010 |
Why?
|
| Adrenal Cortex Function Tests | 1 | 1979 | 8 | 0.010 |
Why?
|
| Depression, Chemical | 1 | 1979 | 52 | 0.010 |
Why?
|
| Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 1983 | 305 | 0.010 |
Why?
|
| Esophageal Neoplasms | 1 | 1993 | 3168 | 0.010 |
Why?
|
| Immunoglobulin Fc Fragments | 1 | 1979 | 47 | 0.010 |
Why?
|
| Nausea | 1 | 1981 | 525 | 0.010 |
Why?
|
| Lymphopenia | 1 | 1981 | 199 | 0.010 |
Why?
|
| Gentamicins | 1 | 1979 | 90 | 0.010 |
Why?
|
| Public Policy | 1 | 1999 | 60 | 0.010 |
Why?
|
| Mycosis Fungoides | 1 | 1982 | 320 | 0.010 |
Why?
|
| Seizures | 1 | 1985 | 989 | 0.010 |
Why?
|
| Anaphylaxis | 1 | 1980 | 119 | 0.010 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 1999 | 208 | 0.010 |
Why?
|
| Peer Review, Research | 1 | 1999 | 66 | 0.010 |
Why?
|
| Adrenocorticotropic Hormone | 1 | 1979 | 156 | 0.010 |
Why?
|
| Hyperkalemia | 1 | 1980 | 79 | 0.010 |
Why?
|
| Neoplasm Staging | 1 | 1994 | 13658 | 0.010 |
Why?
|
| Breast Neoplasms | 3 | 2004 | 15694 | 0.010 |
Why?
|
| Cellulitis | 2 | 1990 | 72 | 0.010 |
Why?
|
| Binding Sites | 2 | 1979 | 2171 | 0.010 |
Why?
|
| Facial Injuries | 1 | 1978 | 30 | 0.010 |
Why?
|
| Mouth Mucosa | 1 | 1979 | 216 | 0.010 |
Why?
|
| Neoplasm Seeding | 1 | 1978 | 66 | 0.010 |
Why?
|
| Anemia, Aplastic | 2 | 1976 | 214 | 0.010 |
Why?
|
| Lysosomes | 1 | 1980 | 347 | 0.010 |
Why?
|
| Neurotoxins | 1 | 1978 | 66 | 0.010 |
Why?
|
| DNA Adducts | 1 | 1998 | 210 | 0.010 |
Why?
|
| Rabbits | 2 | 1980 | 957 | 0.010 |
Why?
|
| Levamisole | 1 | 1977 | 12 | 0.010 |
Why?
|
| Colorectal Neoplasms | 1 | 1993 | 3578 | 0.010 |
Why?
|
| Propionibacterium acnes | 1 | 1977 | 25 | 0.010 |
Why?
|
| Hormones | 1 | 1979 | 266 | 0.010 |
Why?
|
| Leukoencephalopathy, Progressive Multifocal | 1 | 1977 | 46 | 0.010 |
Why?
|
| Lymphatic Diseases | 1 | 1978 | 128 | 0.010 |
Why?
|
| Thyrotropin-Releasing Hormone | 2 | 1991 | 20 | 0.010 |
Why?
|
| Radionuclide Imaging | 2 | 1977 | 660 | 0.010 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 1993 | 5437 | 0.010 |
Why?
|
| Area Under Curve | 1 | 1998 | 700 | 0.010 |
Why?
|
| Clinical Protocols | 1 | 1999 | 467 | 0.010 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 1981 | 673 | 0.010 |
Why?
|
| Blindness | 1 | 1977 | 77 | 0.010 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 1999 | 604 | 0.010 |
Why?
|
| Chickens | 1 | 1976 | 523 | 0.010 |
Why?
|
| Psychoses, Substance-Induced | 1 | 1976 | 15 | 0.010 |
Why?
|
| Immunosuppressive Agents | 1 | 1982 | 1375 | 0.010 |
Why?
|
| Ascitic Fluid | 1 | 1976 | 76 | 0.010 |
Why?
|
| Injections, Intra-Articular | 1 | 1975 | 32 | 0.010 |
Why?
|
| Cold Temperature | 1 | 1976 | 121 | 0.010 |
Why?
|
| Diagnosis, Differential | 1 | 1985 | 4744 | 0.010 |
Why?
|
| Transaminases | 1 | 1996 | 76 | 0.010 |
Why?
|
| Immunologic Deficiency Syndromes | 1 | 1978 | 238 | 0.010 |
Why?
|
| Pregnancy Complications | 1 | 1980 | 526 | 0.010 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 1993 | 5319 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 4 | 1 | 1995 | 108 | 0.010 |
Why?
|
| RNA, Neoplasm | 2 | 1989 | 771 | 0.010 |
Why?
|
| Brain Stem | 1 | 1996 | 175 | 0.010 |
Why?
|
| Blotting, Southern | 1 | 1995 | 406 | 0.010 |
Why?
|
| Thymidylate Synthase | 1 | 1995 | 53 | 0.010 |
Why?
|
| Palmitic Acids | 1 | 1974 | 19 | 0.010 |
Why?
|
| Stereoisomerism | 1 | 1995 | 164 | 0.010 |
Why?
|
| Arachidonic Acids | 1 | 1974 | 29 | 0.010 |
Why?
|
| Tritium | 1 | 1974 | 200 | 0.010 |
Why?
|
| Drug Tolerance | 1 | 1995 | 114 | 0.010 |
Why?
|
| Immune Sera | 1 | 1974 | 146 | 0.010 |
Why?
|
| Gene Library | 1 | 1995 | 294 | 0.010 |
Why?
|
| Knee Joint | 1 | 1975 | 161 | 0.010 |
Why?
|
| Air Microbiology | 1 | 1974 | 30 | 0.010 |
Why?
|
| Regression Analysis | 2 | 1990 | 1546 | 0.010 |
Why?
|
| Adenocarcinoma | 1 | 1993 | 7789 | 0.010 |
Why?
|
| Drug Resistance, Multiple | 1 | 1995 | 204 | 0.010 |
Why?
|
| Granulomatous Disease, Chronic | 1 | 1974 | 79 | 0.010 |
Why?
|
| Multienzyme Complexes | 1 | 1995 | 213 | 0.010 |
Why?
|
| Histocompatibility | 1 | 1974 | 168 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 11 | 1 | 1995 | 402 | 0.010 |
Why?
|
| Transfusion Reaction | 1 | 1974 | 102 | 0.010 |
Why?
|
| Nucleic Acid Hybridization | 2 | 1987 | 542 | 0.010 |
Why?
|
| Antigens, Neoplasm | 2 | 1981 | 1506 | 0.010 |
Why?
|
| Transplantation, Heterologous | 1 | 1995 | 1082 | 0.010 |
Why?
|
| Sarcoma, Kaposi | 1 | 1995 | 187 | 0.010 |
Why?
|
| DNA Primers | 1 | 1995 | 1399 | 0.010 |
Why?
|
| Stroke Volume | 1 | 1996 | 577 | 0.010 |
Why?
|
| Recombination, Genetic | 2 | 1987 | 613 | 0.010 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 1998 | 2232 | 0.010 |
Why?
|
| Neoplasm Transplantation | 1 | 1995 | 1519 | 0.010 |
Why?
|
| Killer Cells, Lymphokine-Activated | 1 | 1992 | 49 | 0.010 |
Why?
|
| Diarrhea | 1 | 1996 | 686 | 0.010 |
Why?
|
| Neutrophils | 2 | 1991 | 835 | 0.010 |
Why?
|
| Triethylenephosphoramide | 1 | 1991 | 2 | 0.010 |
Why?
|
| Cell Movement | 2 | 1977 | 2466 | 0.010 |
Why?
|
| Gene Rearrangement | 1 | 1995 | 783 | 0.010 |
Why?
|
| Antigens, Differentiation, B-Lymphocyte | 1 | 1991 | 47 | 0.010 |
Why?
|
| Mice, SCID | 1 | 1995 | 1869 | 0.010 |
Why?
|
| Immunoglobulin Heavy Chains | 2 | 1983 | 247 | 0.010 |
Why?
|
| Prolactin | 2 | 1982 | 155 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 2 | 1979 | 6942 | 0.010 |
Why?
|
| Lipid Metabolism | 1 | 1974 | 483 | 0.010 |
Why?
|
| Arabinofuranosylcytosine Triphosphate | 1 | 1990 | 75 | 0.010 |
Why?
|
| Intelligence Tests | 1 | 1990 | 88 | 0.010 |
Why?
|
| Li-Fraumeni Syndrome | 1 | 1992 | 158 | 0.010 |
Why?
|
| Retrospective Studies | 2 | 2010 | 37905 | 0.010 |
Why?
|
| Thyroid Hormones | 1 | 1991 | 111 | 0.010 |
Why?
|
| Lung Neoplasms | 1 | 1993 | 11538 | 0.010 |
Why?
|
| Hodgkin Disease | 1 | 1979 | 1429 | 0.010 |
Why?
|
| Proportional Hazards Models | 1 | 1998 | 4988 | 0.010 |
Why?
|
| RNA Probes | 1 | 1989 | 44 | 0.010 |
Why?
|
| Agammaglobulinemia | 2 | 1981 | 46 | 0.010 |
Why?
|
| Spine | 1 | 1991 | 293 | 0.010 |
Why?
|
| Polymerase Chain Reaction | 1 | 1995 | 3203 | 0.010 |
Why?
|
| Succinimides | 1 | 1989 | 7 | 0.010 |
Why?
|
| Analysis of Variance | 1 | 1993 | 2307 | 0.010 |
Why?
|
| Ricin | 1 | 1989 | 34 | 0.010 |
Why?
|
| Disease Models, Animal | 2 | 1999 | 7222 | 0.010 |
Why?
|
| Body Fluids | 1 | 1990 | 125 | 0.010 |
Why?
|
| Flow Cytometry | 1 | 1995 | 3033 | 0.010 |
Why?
|
| Molecular Weight | 1 | 1989 | 629 | 0.010 |
Why?
|
| Cross-Linking Reagents | 1 | 1989 | 153 | 0.010 |
Why?
|
| Verapamil | 1 | 1988 | 78 | 0.010 |
Why?
|
| Binding, Competitive | 1 | 1989 | 300 | 0.010 |
Why?
|
| Glucose | 1 | 1974 | 1248 | 0.010 |
Why?
|
| Arginine | 2 | 1982 | 500 | 0.000 |
Why?
|
| RNA, Messenger | 2 | 1988 | 6150 | 0.000 |
Why?
|
| CD3 Complex | 1 | 1988 | 314 | 0.000 |
Why?
|
| Triglycerides | 2 | 1982 | 603 | 0.000 |
Why?
|
| Repetitive Sequences, Nucleic Acid | 1 | 1988 | 362 | 0.000 |
Why?
|
| Pregnancy | 1 | 1980 | 7573 | 0.000 |
Why?
|
| KB Cells | 1 | 1987 | 18 | 0.000 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 1995 | 3890 | 0.000 |
Why?
|
| Antigens, CD | 1 | 1992 | 1385 | 0.000 |
Why?
|
| Gene Expression Regulation | 2 | 1989 | 4053 | 0.000 |
Why?
|
| Incidence | 1 | 1997 | 5673 | 0.000 |
Why?
|
| RNA Splicing | 1 | 1988 | 370 | 0.000 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 1995 | 2359 | 0.000 |
Why?
|
| Severity of Illness Index | 1 | 1997 | 4320 | 0.000 |
Why?
|
| Polymorphism, Genetic | 1 | 1992 | 1450 | 0.000 |
Why?
|
| Adaptation, Psychological | 1 | 1990 | 764 | 0.000 |
Why?
|
| Vinblastine | 1 | 1987 | 453 | 0.000 |
Why?
|
| Bilirubin | 1 | 1987 | 221 | 0.000 |
Why?
|
| Insulin | 2 | 1982 | 1454 | 0.000 |
Why?
|
| Glioblastoma | 1 | 1996 | 1797 | 0.000 |
Why?
|
| Brain Damage, Chronic | 1 | 1984 | 37 | 0.000 |
Why?
|
| Genetic Markers | 1 | 1987 | 974 | 0.000 |
Why?
|
| Interphase | 1 | 1984 | 145 | 0.000 |
Why?
|
| Fasting | 1 | 1986 | 349 | 0.000 |
Why?
|
| Disease-Free Survival | 1 | 1996 | 10001 | 0.000 |
Why?
|
| Atrophy | 1 | 1984 | 261 | 0.000 |
Why?
|
| Reaction Time | 1 | 1984 | 234 | 0.000 |
Why?
|
| Eating | 1 | 1986 | 421 | 0.000 |
Why?
|
| Genetic Code | 1 | 1983 | 32 | 0.000 |
Why?
|
| Streptodornase and Streptokinase | 1 | 1982 | 2 | 0.000 |
Why?
|
| Transcriptional Activation | 1 | 1987 | 1070 | 0.000 |
Why?
|
| Bone Marrow Cells | 1 | 1987 | 943 | 0.000 |
Why?
|
| Methods | 1 | 1982 | 189 | 0.000 |
Why?
|
| Bacteria | 1 | 1987 | 611 | 0.000 |
Why?
|
| Survival Rate | 1 | 1996 | 12221 | 0.000 |
Why?
|
| Gonadotropins | 1 | 1982 | 50 | 0.000 |
Why?
|
| Deoxyribonuclease BamHI | 1 | 1981 | 2 | 0.000 |
Why?
|
| Levodopa | 1 | 1982 | 92 | 0.000 |
Why?
|
| DNA Restriction Enzymes | 1 | 1981 | 117 | 0.000 |
Why?
|
| Immunoglobulin Light Chains | 1 | 1981 | 109 | 0.000 |
Why?
|
| Candida | 1 | 1982 | 164 | 0.000 |
Why?
|
| Carboxylic Ester Hydrolases | 1 | 1981 | 14 | 0.000 |
Why?
|
| Sperm Count | 1 | 1981 | 100 | 0.000 |
Why?
|
| Goats | 1 | 1980 | 73 | 0.000 |
Why?
|
| Puberty | 1 | 1981 | 104 | 0.000 |
Why?
|
| Antigen-Antibody Complex | 1 | 1980 | 115 | 0.000 |
Why?
|
| Acetazolamide | 1 | 1980 | 36 | 0.000 |
Why?
|
| Cerebral Cortex | 1 | 1984 | 621 | 0.000 |
Why?
|
| Genetic Variation | 1 | 1988 | 2086 | 0.000 |
Why?
|
| Stem Cells | 1 | 1987 | 1213 | 0.000 |
Why?
|
| Uric Acid | 1 | 1980 | 75 | 0.000 |
Why?
|
| Gonadotropin-Releasing Hormone | 1 | 1981 | 167 | 0.000 |
Why?
|
| Hemocyanins | 1 | 1979 | 50 | 0.000 |
Why?
|
| Neoplasm Metastasis | 2 | 1982 | 5112 | 0.000 |
Why?
|
| Listeriosis | 1 | 1979 | 35 | 0.000 |
Why?
|
| Carcinoma, Renal Cell | 1 | 1992 | 2326 | 0.000 |
Why?
|
| Fever of Unknown Origin | 1 | 1979 | 63 | 0.000 |
Why?
|
| Transcription, Genetic | 1 | 1987 | 3154 | 0.000 |
Why?
|
| Cerebral Ventriculography | 1 | 1977 | 2 | 0.000 |
Why?
|
| Endotoxins | 1 | 1978 | 96 | 0.000 |
Why?
|
| Histiocytes | 1 | 1978 | 94 | 0.000 |
Why?
|
| Carmustine | 1 | 1978 | 214 | 0.000 |
Why?
|
| Gold Colloid, Radioactive | 1 | 1977 | 1 | 0.000 |
Why?
|
| Immune Tolerance | 1 | 1979 | 403 | 0.000 |
Why?
|
| Biopharmaceutics | 1 | 1977 | 1 | 0.000 |
Why?
|
| Dactinomycin | 1 | 1977 | 145 | 0.000 |
Why?
|
| Dose-Response Relationship, Immunologic | 1 | 1977 | 182 | 0.000 |
Why?
|
| Longitudinal Studies | 1 | 1982 | 1945 | 0.000 |
Why?
|
| Prospective Studies | 2 | 1982 | 12873 | 0.000 |
Why?
|
| Syndrome | 1 | 1980 | 1351 | 0.000 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 1989 | 2390 | 0.000 |
Why?
|
| Lymphocyte Culture Test, Mixed | 1 | 1975 | 88 | 0.000 |
Why?
|
| Hyperlipidemias | 1 | 1978 | 235 | 0.000 |
Why?
|
| Spleen | 1 | 1978 | 676 | 0.000 |
Why?
|
| Optic Nerve | 1 | 1977 | 133 | 0.000 |
Why?
|
| Myocarditis | 1 | 1978 | 190 | 0.000 |
Why?
|
| Lectins | 1 | 1975 | 151 | 0.000 |
Why?
|
| Antibodies, Neoplasm | 1 | 1975 | 259 | 0.000 |
Why?
|
| Melanoma | 1 | 1992 | 5317 | 0.000 |
Why?
|
| Hematopoietic Stem Cells | 1 | 1981 | 1242 | 0.000 |
Why?
|
| Histocompatibility Antigens | 1 | 1974 | 74 | 0.000 |
Why?
|
| Anti-Bacterial Agents | 1 | 1987 | 2992 | 0.000 |
Why?
|
| Monitoring, Physiologic | 1 | 1977 | 502 | 0.000 |
Why?
|
| Antigens, Viral | 1 | 1976 | 471 | 0.000 |
Why?
|
| Hepatitis B virus | 1 | 1976 | 217 | 0.000 |
Why?
|
| Blood Cell Count | 1 | 1974 | 225 | 0.000 |
Why?
|
| Immunization | 1 | 1975 | 397 | 0.000 |
Why?
|
| Cell Division | 1 | 1978 | 2489 | 0.000 |
Why?
|
| Blood Donors | 1 | 1974 | 164 | 0.000 |
Why?
|
| Histocompatibility Testing | 1 | 1974 | 447 | 0.000 |
Why?
|
| Chronic Disease | 1 | 1976 | 1819 | 0.000 |
Why?
|
| Antibodies, Viral | 1 | 1976 | 1320 | 0.000 |
Why?
|